Drug Trial Radar · NCT01327846
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Last checked: Nov 19, 2026Latest source record: Jan 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10,066
Actual
Start
Apr 11, 2011
Primary completion
Mar 28, 2017
Study completion Apr 14, 2019
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 4, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Main Study (CACZ885M2301): The purpose of the pivotal phase of this trial was to test the hypothesis that canakinumab treatment of patients with myocardial infarction (MI) at least one month prior to study entry and elevated hsCRP could prevent recurrent cardiovascular events. The purpose of the extension phase of the main study is to collect additional long-term safety data on continued exposure to canakinumab in patients who participated in the pivotal phase. Sub-study 1 (CACZ885M2301S1): The purpose of this sub-study was to evaluate the effect of quarterly subcutaneous canakinumab treatment for 24 months comparted with placebo on the carotid plaque burden measured by integrated vascular MRI in patients enrolled in the CACZ885M2301 study (CANTOS). Sub-study 2 (CACZ885M2301S2): The purpose of this CANTOS sub-study was to determine whether, in patients with type 2 diabetes participating in the CANTOS main study, canakinumab compared to placebo, on top of standard of care could increase insulin secretion and insulin sensitivity.
Conditions
- Atherosclerosis
Interventions
CanakinumabDrug
PlaceboDrug
Standard of careDrug
Standard of care post-MI background therapy includes, but is not limited to, lipid lowering, anti-hypertensive, beta blockers, and anti-platelet therapy as appropriate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Analysis of Core Phase First CEC Confirmed Major Adverse Cardiovascular Events (MACE) and Its ComponentsTime frame: From randomization, to end of treatment plus 30 days, up to approximately 6 years
- Substudy 1 (Core Phase): Change From Baseline in Carotid Plaque Burden in the Bifurcation Region of the Index Carotid ArteryTime frame: 24 months
- Substudy 2 (Core Phase): Change From Baseline of the Insulin Secretion Rate (ISR) Relative to Glucose 0-30 Min Defined as Φ30 = AUCISR 0-30 / AUCGluc 0-30 Averaged Across the Year 3, 4, 5 VisitsTime frame: From randomization up to approximately 6 years
Locations
1,131 sites in 40 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Athens, Alabama
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Fairhope, Alabama
Novartis Investigative Site
Huntsville, Alabama
Novartis Investigative Site
Mobile, Alabama
Novartis Investigative Site
Mobile, Alabama
Novartis Investigative Site
Mobile, Alabama
Novartis Investigative Site
Anchorage, Alaska
Novartis Investigative Site
Chandler, Arizona
Novartis Investigative Site
Glendale, Arizona
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Hot Springs, Arkansas
Novartis Investigative Site
Jonesboro, Arkansas
Novartis Investigative Site
Little Rock, Arkansas
Novartis Investigative Site
Beverly Hills, California
Novartis Investigative Site
Carmichael, California
Novartis Investigative Site
Escondido, California
Novartis Investigative Site
Fullerton, California
Novartis Investigative Site
Huntington Beach, California
Novartis Investigative Site
Lancaster, California
Novartis Investigative Site
Loma Linda, California
Novartis Investigative Site
Loma Linda, California
Novartis Investigative Site
Long Beach, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Los Gatos, California
Novartis Investigative Site
Mission Viejo, California
Novartis Investigative Site
Newport Beach, California
Novartis Investigative Site
Northridge, California
Novartis Investigative Site
Oceanside, California
Novartis Investigative Site
Orangevale, California
Novartis Investigative Site
Palm Springs, California
Novartis Investigative Site
Pasadena, California
Novartis Investigative Site
Pomona, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
San Diego, California
Showing 40 of 1,131 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.